Cryptophycin

Drug Profile

Cryptophycin

Latest Information Update: 18 Dec 2007

Price : $50

At a glance

  • Originator Unknown
  • Developer Eli Lilly; Nonindustrial source
  • Class Antifungals; Antineoplastics; Cyclic peptides; Depsipeptides
  • Mechanism of Action Microtubule protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer; Solid tumours

Most Recent Events

  • 13 Jul 2000 Phase-II clinical trials for Solid tumours in USA (Unknown route)
  • 08 Jun 1999 A preclinical study has been added to the pharmacodynamics section
  • 11 Apr 1997 No-Development-Reported for Cancer in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top